Eli Lilly’s retatrutide meets primary goals in phase 3 obesity trials with ~22% weight loss but no clear heart benefit

Eli Lilly reported that its triple‑hormone agonist retatrutide achieved the primary endpoints in two phase 3 obesity studies, TRIUMPH‑2 and TRIUMPH‑3. The drug was tested at a 12 mg dose against placebo in patients with type 2 diabetes and obesity, as well as in those with severe obesity and established cardiovascular disease.

In TRIUMPH‑2, participants lost an average of 20.8% of body weight after 80 weeks, while the placebo group lost 3.2%. In the larger TRIUMPH‑3 trial, the average weight loss was 22.6% versus 3.2% for placebo, confirming statistically significant efficacy.

These reductions, although impressive, fell short of earlier trial results that showed nearly 29% weight loss. Moreover, the studies did not demonstrate a clear benefit in reducing cardiovascular risk, leaving that key outcome unresolved.

The findings reinforce retatrutide’s potential as a weight‑loss therapy but suggest further data will be needed to establish its cardiovascular advantages before broader clinical adoption.